LME(SH:688589)2022-04-22 16:00Financial Performance - The company's operating revenue for Q1 2022 was ¥97,371,399.16, representing a year-on-year increase of 138.30%[5] - Net profit attributable to shareholders reached ¥13,475,172.22, a significant increase of 950.61% compared to the same period last year[5] - Basic and diluted earnings per share were both ¥0.13, reflecting a growth of 1,200.00% year-on-year[5] - Total operating revenue for Q1 2022 reached ¥97,371,399.16, a significant increase of 138.5% compared to ¥40,861,255.18 in Q1 2021[16] - Net profit for Q1 2022 was ¥13,475,172.22, compared to ¥1,282,601.14 in Q1 2021, reflecting a growth of 950.5%[18] - Earnings per share for Q1 2022 were ¥0.13, significantly higher than ¥0.01 in Q1 2021[18] - Total comprehensive income of ¥13,467,912.05 for Q1 2022, compared to ¥1,287,585.54 in Q1 2021[18] - Total comprehensive income for Q1 2022 was -¥2,229,687.98, compared to ¥471,948.24 in Q1 2021, indicating a significant decline[28] Cash Flow - The net cash flow from operating activities was -¥33,934,532.58, a decrease of 1,075.08% year-on-year, primarily due to increased inventory and procurement of chips and raw materials[5][8] - In Q1 2022, the cash inflow from operating activities was CNY 96,493,683.88, a significant increase from CNY 44,979,235.21 in Q1 2021, representing a growth of approximately 114%[20] - The cash outflow from operating activities totaled CNY 130,428,216.46, compared to CNY 47,867,087.39 in the previous year, resulting in a net cash flow from operating activities of -CNY 33,934,532.58, worsening from -CNY 2,887,852.18[20] - The company reported a net cash flow from operating activities of -¥19,504,418.83 for Q1 2022, worsening from -¥12,073,090.03 in Q1 2021[29] Research and Development - Total R&D investment amounted to ¥15,425,316.44, an increase of 35.72% compared to the previous year, indicating the company's commitment to innovation[6] - Research and development expenses for Q1 2022 were ¥15,425,316.44, up 36.5% from ¥11,365,358.46 in Q1 2021[16] - Research and development expenses increased to ¥11,444,897.06 in Q1 2022, up from ¥8,000,216.56 in Q1 2021, reflecting a focus on innovation[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥961,120,871.39, a slight decrease of 0.84% from the previous year-end[6] - The equity attributable to shareholders increased to ¥762,177,652.24, reflecting a growth of 2.13% compared to the previous year-end[6] - The company's total assets amounted to ¥953,076,880.34, a slight decrease from ¥961,120,871.39 at the end of 2021, reflecting a decrease of approximately 0.5%[12] - The company's total liabilities were reported at ¥838,143,212.48, reflecting a decrease from the previous total of ¥846,922,399.31, indicating a decline of about 1.0%[13] - Total liabilities decreased to ¥190,899,228.10 in Q1 2022 from ¥214,846,743.49 in Q1 2021, a reduction of 11.1%[16] - The total liabilities increased to CNY 288,308,291.55 from CNY 273,648,671.82, marking an increase of about 5.3%[25] Inventory and Receivables - The accounts receivable increased to ¥219,416,741.40 from ¥227,047,874.19, showing a decrease of about 3.4%[12] - Inventory levels rose to ¥88,329,689.38, compared to ¥75,770,079.53 at the end of 2021, marking an increase of approximately 16.5%[12] - The inventory as of March 31, 2022, was CNY 131,485,265.51, an increase from CNY 112,504,250.65 in the previous year, representing a growth of about 16.9%[24] - The accounts receivable stood at CNY 200,181,726.44, slightly down from CNY 209,617,341.23, indicating a decrease of approximately 4.1%[24] Other Financial Metrics - The weighted average return on net assets was 1.79%, up by 1.61 percentage points from the previous year[6] - The company reported non-recurring gains of ¥3,899,699.16, after accounting for tax impacts[8] - The company incurred sales expenses of ¥7,402,023.40 in Q1 2022, an increase from ¥5,051,585.07 in Q1 2021[26] - The financial expenses for Q1 2022 were -¥157,536.77, showing an improvement from -¥300,145.78 in Q1 2021[26]